Evidence map›Paper›PMID 36967843›Full record

ArticlePostepy w kardiologii interwencyjnej = Advances in interventional cardiology2022

Acute myocardial infarction reparation/regeneration strategy using Wharton's jelly multipotent stem cells as an 'unlimited' therapeutic agent: 3-year outcomes in a pilot cohort of the CIRCULATE-AMI trial.

Ewa Kwiecien, Leszek Drabik, Adam Mazurek, Danuta Jarocha, Malgorzata Urbanczyk, Wojciech Szot, Robert P Banys, Anna Kozynacka-Fras, Wojciech Plazak, Maria Olszowska and 5 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Postepy w kardiologii interwencyjnej = Advances in interventional cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03404063 (Regeneration of Ischemic Damages in Cardiovascular System Using Wharton's Jelly as an Unlimited Source of Mesenchymal Stem Cells for Regenerative Medicine. Project of the National Centre for Research and Development), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03404063 phase2 / phase3completednot on this map

Regeneration of Ischemic Damages in Cardiovascular System Using Wharton's Jelly as an Unlimited Source of Mesenchymal Stem Cells for Regenerative Medicine. Project of the National Centre for Research and Development (Poland) 'STRATEGMED II'. Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With Acute Myocardial Infarction (AMI).

TypeinterventionalSponsorJohn Paul II Hospital, KrakowRan2017 to 2021Enrolled105ConditionsMyocardial InfarctionArmsCardiac Drug, Placebos
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Ewa KwiecienDepartment of Cardiac and Vascular Diseases, Jagiellonian University, Krakow, Poland.
Leszek DrabikDepartment of Cardiac and Vascular Diseases, Jagiellonian University, Krakow, Poland.
Adam MazurekDepartment of Cardiac and Vascular Diseases, Jagiellonian University, Krakow, Poland.
Danuta JarochaDepartment of Transplantation, John Paul II Hospital, Krakow, Poland.
Malgorzata UrbanczykMagnetic Resonance Imaging Laboratory, Krakow, Poland.
Wojciech SzotNuclear Imaging Laboratory, Krakow, Poland.
Robert P BanysMagnetic Resonance Imaging Laboratory, Krakow, Poland.
Anna Kozynacka-FrasClinical Department, John Paul II Hospital, Krakow, Poland.
Wojciech PlazakDepartment of Cardiac and Vascular Diseases, Jagiellonian University, Krakow, Poland.
Maria OlszowskaDepartment of Cardiac and Vascular Diseases, Jagiellonian University, Krakow, Poland.
Dorota SobczykClinical Department, John Paul II Hospital, Krakow, Poland.
Magdalena KostkiewiczClinical Department, John Paul II Hospital, Krakow, Poland.
Marcin MajkaDepartment of Transplantation, John Paul II Hospital, Krakow, Poland.
Piotr PodolecDepartment of Cardiac and Vascular Diseases, Jagiellonian University, Krakow, Poland.
Piotr MusialekDepartment of Cardiac and Vascular Diseases, Jagiellonian University, Krakow, Poland.
Jagiellonian University · PLJohn Paul II Hospital · PLChildren's Hospital of Philadelphia · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: CIRCULATE-AMI (NCT03404063), a cardiac magnetic resonance imaging (cMRI) infarct size-reduction-powered double-blind randomized controlled trial (RCT) of standardized Wharton jelly multipotent stem cells (WJMSCs, CardioCell Investigational Medical Product) vs. placebo (2 : 1) transcoronary transfer on acute myocardial infarction (AMI) day ~5-7, is preceded by safety and feasibility evaluation in a pilot study cohort (CIRCULATE-AMI PSC). Aim: To evaluate WJMSC transplantation safety and evolution of left ventricular (LV) remodeling in CIRCULATE-AMI PSC. Material and methods: In 10 consecutive patients (32-65 years, peak CK-MB 533 ±89 U/l, cMRI-LVEF 40.3 ±2.7%, cMRI-infarct size 20.1 ±2.8%), 30 × 10 Results: WJMSC transfer was safe and occurred in the absence of coronary (TIMI-3 in all) or myocardial (corrected TIMI frame count (cTFC) 45 ±8 vs. 44 ±9, Conclusions: CIRCULATE-AMI PSC data suggest that WJMSC transcoronary application ~5-7 days after large AMI in humans is feasible and safe and it may be associated with a durable LVEF improvement. CIRCULATE-AMI RCT will quantify the magnitude of LV adverse remodeling attenuation with CardioCell/placebo administration.

Indexed as

efficacyinfarct sizeLV ejection fractionmyocardial regenerationsafetyWharton’s jelly multipotent stem cells

Identifiers

PMID36967843
PMCPMC10031665
OpenAlexW4312378017

What Socratic holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.